# Henry F Chambers

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 92 papers | 12,812 citations | 109321 35 h-index | 53230 85 g-index |
| 95 all docs | 95 docs citations | 95 times ranked | 12411 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Patient-Directed Discharges Among Persons Who Use Drugs Hospitalized with Invasive Staphylococcus aureus Infections: Opportunities for Improvement. American Journal of Medicine, 2022, 135, 91-96. | 1.5 | 11 |
| 2 | Loss of GdpP Function in Staphylococcus aureus Leads to Î²-Lactam Tolerance and Enhanced Evolution of Î²-Lactam Resistance. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0143121. | 3.2 | 8 |
| 3 | Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infectious Diseases, The, 2022, 22, 401-412. | 9.1 | 122 |
| 4 | Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children. JAMA Pediatrics, 2022, 176, 253. | 6.2 | 66 |
| 5 | Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections. Open Forum Infectious Diseases, 2022, 9, ofab651. | 0.9 | 6 |
| 6 | Impacts of NaHCO3 on Î²-Lactam Binding to PBP2a Protein Variants Associated with the NaHCO3-Responsive versus NaHCO3-Non-Responsive Phenotypes. Antibiotics, 2022, 11, 462. | 3.7 | 4 |
| 7 | Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX. MBio, 2022, 13, e0049722. | 4.1 | 17 |
| 8 | Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia. Journal of Infectious Diseases, 2022, 226, 1109-1119. | 4.0 | 6 |
| 9 | The NaHCO <sub>3</sub> -Responsive Phenotype in Methicillin-Resistant Staphylococcus aureus (MRSA) Is Influenced by <i>mecA</i> Genotype. Antimicrobial Agents and Chemotherapy, 2022, 66, e0025222. | 3.2 | 3 |
| 10 | Differential Trends in Extended-Spectrum Beta-Lactamase-Producing <i>Escherichia coli</i> Infections in Four Health Care Facilities in a Single Metropolitan Area: A Retrospective Analysis. Microbial Drug Resistance, 2021, 27, 154-161. | 2.0 | 1 |
| 11 | Skin and Soft Tissue Infections in Persons Who Inject Drugs. Infectious Disease Clinics of North America, 2021, 35, 169-181. | 5.1 | 21 |
| 12 | Antibacterial Resistance Leadership Group 2.0: Back to Business. Clinical Infectious Diseases, 2021, 73, 730-739. | 5.8 | 7 |
| 13 | Prosthetic Valve Endocarditis Diagnosis and Managementâ€" New Paradigm Shift Narratives. Clinical Infectious Diseases, 2021, 72, 1687-1692. | 5.8 | 5 |
| 14 | Skin and Soft Tissue Infections. Infectious Disease Clinics of North America, 2021, 35, xiii-xiv. | 5.1 | 2 |
| 15 | Impact of Bicarbonate on PBP2a Production, Maturation, and Functionality in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2021, 65, . | 3.2 | 9 |
| 16 | Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system. Antimicrobial Resistance and Infection Control, 2021, 10, 118. | 4.1 | 22 |
| 17 | A Combined Phenotypic-Genotypic Predictive Algorithm for In Vitro Detection of Bicarbonate: Î²-Lactam Sensitization among Methicillin-Resistant Staphylococcus aureus (MRSA). Antibiotics, 2021, 10, 1089. | 3.7 | 7 |
| 18 | Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity. Lancet Infectious Diseases, The, 2021, 21, e296-e301. | 9.1 | 57 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Impact of Bicarbonate-Î²-Lactam Exposures on Methicillin-Resistant Staphylococcus aureus (MRSA) Gene Expression in Bicarbonate-Î²-Lactam-Responsive vs. Non-Responsive Strains. Genes, 2021, 12, 1650. | 2.4 | 7 |
| 20 | The Emperorâ€™s New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clinical Infectious Diseases, 2020, 70, 1536-1545. | 5.8 | 106 |
| 21 | Antimicrobial Drug Development Efficiency and Surrogate Markers of Clinical Benefit. JAMA Internal Medicine, 2020, 180, 138. | 5.1 | 1 |
| 22 | Native-Valve Infective Endocarditis. New England Journal of Medicine, 2020, 383, 567-576. | 27.0 | 85 |
| 23 | Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. Journal of Antimicrobial Chemotherapy, 2020, 75, 2622-2632. | 3.0 | 39 |
| 24 | Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis. JAMA Internal Medicine, 2020, 180, 769. | 5.1 | 44 |
| 25 | Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infectious Diseases, The, 2020, 20, 731-741. | 9.1 | 174 |
| 26 | Structural analysis of avibactam-mediated activation of the bla and mec divergons in methicillin-resistant Staphylococcus aureus. Journal of Biological Chemistry, 2020, 295, 10870-10884. | 3.4 | 7 |
| 27 | Rifabutin to the Rescue?. Journal of Infectious Diseases, 2020, 222, 1422-1424. | 4.0 | 2 |
| 28 | Analytical Evaluation of the Abbott RealTime CT/NG Assay for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Rectal and Pharyngeal Swabs. Journal of Molecular Diagnostics, 2020, 22, 811-816. | 2.8 | 8 |
| 29 | Scope and Predictive Genetic/Phenotypic Signatures of Bicarbonate (NaHCO <sub>3</sub> ) Responsiveness and Î²-Lactam Sensitization in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 13 |
| 30 | 175. Randomized Double-blind Controlled Trial of Short vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP). Open Forum Infectious Diseases, 2020, 7, S216-S216. | 0.9 | 1 |
| 31 | 39. Comparative One-year Outcomes of Invasive <i>staphylococcus Aureus</i> infections Among Persons with and Without Drug Use in an Urban West Coast Cohort. Open Forum Infectious Diseases, 2020, 7, S20-S21. | 0.9 | 0 |
| 32 | A Prognostic Model of Persistent Bacteremia and Mortality in Complicated Staphylococcus aureus Bloodstream Infection. Clinical Infectious Diseases, 2019, 68, 1502-1511. | 5.8 | 36 |
| 33 | Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 9 |
| 34 | Bicarbonate Resensitization of Methicillin-Resistant <i>Staphylococcus aureus</i> to Î²-Lactam Antibiotics. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 27 |
| 35 | Omadacycline â€" The Newest Tetracycline. New England Journal of Medicine, 2019, 380, 588-589. | 27.0 | 20 |
| 36 | 2276. Clinical Epidemiology of the Carbapenem-Resistant Enterobacteriaceae (CRE) Epidemic in Colombia: A Multicenter Prospective Study. Open Forum Infectious Diseases, 2019, 6, S779-S779. | 0.9 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | 607. Scope and Predictive Genetic/Phenotypic Signatures of â€œBicarbonate [NaHCO3]-Responsivityâ€•and Î²-Lactam Sensitization among Methicillin-Resistant Staphylococcus aureus (MRSA). Open Forum Infectious Diseases, 2019, 6, S284-S284. | 0.9 | 0 |
| 38 | Considerations for Clinical Trials of <i>Staphylococcus aureus</i> Bloodstream Infection in Adults. Clinical Infectious Diseases, 2019, 68, 865-872. | 5.8 | 38 |
| 39 | Clinical Practice Variation Among Adult Infectious Disease Physicians in the Management of <i>Staphylococcus aureus</i> Bacteremia. Clinical Infectious Diseases, 2019, 69, 530-533. | 5.8 | 44 |
| 40 | Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV. Clinical Infectious Diseases, 2019, 68, 1823-1830. | 5.8 | 37 |
| 41 | PBP4 activity and its overexpression are necessary for PBP4-mediated high-level Î²-lactam resistance. Journal of Antimicrobial Chemotherapy, 2018, 73, 1177-1180. | 3.0 | 19 |
| 42 | Structural and kinetic analyses of penicillin-binding protein 4 (PBP4)-mediated antibiotic resistance in Staphylococcus aureus. Journal of Biological Chemistry, 2018, 293, 19854-19865. | 3.4 | 44 |
| 43 | PBP4: A New Perspective on Staphylococcus aureus Î²-Lactam Resistance. Microorganisms, 2018, 6, 57. | 3.6 | 34 |
| 44 | Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 24 |
| 45 | Can Ceftazidime-Avibactam and Aztreonam Overcome Î²-Lactam Resistance Conferred by Metallo-Î²-Lactamases in Enterobacteriaceae?. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 217 |
| 46 | High-Level Resistance of Staphylococcus aureus to Î²-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4). Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 44 |
| 47 | Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 24 |
| 48 | PBP4 Mediates Î²-Lactam Resistance by Altered Function. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 30 |
| 49 | Antimicrobial Stewardship Approaches in the Intensive Care Unit. Infectious Disease Clinics of North America, 2017, 31, 513-534. | 5.1 | 24 |
| 50 | A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. New England Journal of Medicine, 2017, 376, 2545-2555. | 27.0 | 156 |
| 51 | Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III. Journal of Clinical Microbiology, 2017, 55, 134-144. | 3.9 | 26 |
| 52 | Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess. Open Forum Infectious Diseases, 2017, 4, ofx232. | 0.9 | 42 |
| 53 | Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia. Infection and Chemotherapy, 2016, 48, 267. | 2.3 | 120 |
| 54 | PBP 4 Mediates High-Level Resistance to New-Generation Cephalosporins in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2016, 60, 3934-3941. | 3.2 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Daptomycinâ€“Î²-Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Endocarditis. Antimicrobial Agents and Chemotherapy, 2016, 60, 3976-3979. | 3.2 | 11 |
| 56 | IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Science Translational Medicine, 2016, 8, 357ra124. | 12.4 | 70 |
| 57 | Reply to Lesho and Clifford. Clinical Infectious Diseases, 2016, 63, 571-572. | 5.8 | 1 |
| 58 | Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia. Antimicrobial Agents and Chemotherapy, 2016, 60, 5276-5284. | 3.2 | 19 |
| 59 | Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. Clinical Infectious Diseases, 2016, 62, 181-189. | 5.8 | 52 |
| 60 | Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance. PLoS ONE, 2016, 11, e0149541. | 2.5 | 53 |
| 61 | Epidemiology of community-associated methicillin-resistant Staphylococcus aureus in San Francisco children. Journal of Pediatric Infectious Diseases, 2015, 04, 247-259. | 0.2 | 0 |
| 62 | USA300 and USA500 Clonal Lineages of Staphylococcus aureus Do Not Produce a Capsular Polysaccharide Due to Conserved Mutations in the <i>cap5</i> Locus. MBio, 2015, 6, . | 4.1 | 82 |
| 63 | Ceftobiprole- and Ceftaroline-Resistant Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2015, 59, 2960-2963. | 3.2 | 69 |
| 64 | Comparative Efficacies of Tedizolid Phosphate, Vancomycin, and Daptomycin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis. Antimicrobial Agents and Chemotherapy, 2015, 59, 3252-3256. | 3.2 | 21 |
| 65 | Clindamycin versus Trimethoprimâ€“Sulfamethoxazole for Uncomplicated Skin Infections. New England Journal of Medicine, 2015, 372, 1093-1103. | 27.0 | 166 |
| 66 | 608Can Rapid Molecular Diagnostics Assist in the Choice of b-Lactam Antibiotics? An Analysis of Data from PRIMERS-II of the Antibiotic Resistance Leadership Group (ARLG). Open Forum Infectious Diseases, 2014, 1, S28-S28. | 0.9 | 1 |
| 67 | Staphylococcus aureus Bacteremia at 5 US Academic Medical Centers, 2008-2011: Significant Geographic Variation in Community-Onset Infections. Clinical Infectious Diseases, 2014, 59, 798-807. | 5.8 | 85 |
| 68 | Probability of Eradication Using Vancomycin Alone or in Combination for Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrobial Agents and Chemotherapy, 2014, 58, 7617-7617. | 3.2 | 1 |
| 69 | Antibacterial Resistance Leadership Group: Open for Business. Clinical Infectious Diseases, 2014, 58, 1571-1576. | 5.8 | 22 |
| 70 | Executive Summary: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2014, 59, 147-159. | 5.8 | 1,156 |
| 71 | Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2014, 59, e10-e52. | 5.8 | 1,711 |
| 72 | Pharmacology and the Treatment of Complicated Skin and Skin-Structure Infections. New England Journal of Medicine, 2014, 370, 2238-2239. | 27.0 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | 724Vancomycin Minimum Inhibitory Concentration Does Not Predict Death, Recurrence or Readmission in Patients with Staphylococcus aureus Bacteremia in a Safety-Net Hospital. Open Forum Infectious Diseases, 2014, 1, S204-S204. | 0.9 | 0 |
| 74 | Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clinical Infectious Diseases, 2011, 52, e18-e55. | 5.8 | 2,673 |
| 75 | Reply to Cataldo et al. Clinical Infectious Diseases, 2011, 53, 310-310. | 5.8 | 0 |
| 76 | A <i>mec</i> <i>A</i> -Negative Strain of Methicillin-Resistant <i>S</i> <i>taphylococcus</i> <i>aureus</i> with High-Level Î²-Lactam Resistance Contains Mutations in Three Genes. Antimicrobial Agents and Chemotherapy, 2010, 54, 4900-4902. | 3.2 | 90 |
| 77 | Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. Journal of Clinical Investigation, 2009, 119, 2464-2474. | 8.2 | 410 |
| 78 | Waves of resistance: Staphylococcus aureus in the antibiotic era. Nature Reviews Microbiology, 2009, 7, 629-641. | 28.6 | 2,049 |
| 79 | Merle A. Sande: 1939â€“2007. Clinical Infectious Diseases, 2008, 46, 1743-1744. | 5.8 | 0 |
| 80 | Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by<i>Staphylococcus aureus</i>. New England Journal of Medicine, 2006, 355, 653-665. | 27.0 | 1,347 |
| 81 | Evaluation of Ceftobiprole in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2005, 49, 884-888. | 3.2 | 94 |
| 82 | Imipenem for Treatment of Tuberculosis in Mice and Humans. Antimicrobial Agents and Chemotherapy, 2005, 49, 2816-2821. | 3.2 | 105 |
| 83 | Daptomycin: Another Novel Agent for Treating Infections Due to Drugâ€Resistant Gramâ€Positive Pathogens. Clinical Infectious Diseases, 2004, 38, 994-1000. | 5.8 | 319 |
| 84 | Solving staphylococcal resistance to Î²-lactams. Trends in Microbiology, 2003, 11, 145-148. | 7.7 | 37 |
| 85 | Efficacy of Levofloxacin for Experimental Aortic-Valve Endocarditis in Rabbits Infected with Viridans Group Streptococcus or<i>Staphylococcus aureus</i>. Antimicrobial Agents and Chemotherapy, 1999, 43, 2742-2746. | 3.2 | 33 |
| 86 | Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine*. Clinical Pharmacology and Therapeutics, 1996, 59, 14-21. | 4.7 | 71 |
| 87 | Ampicillin, Sulbactam, and Rifampin Combination Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Endocarditis in Rabbits. Journal of Infectious Diseases, 1995, 171, 897-902. | 4.0 | 34 |
| 88 | Efficacy of cefoperazone in combination with sulbactam in experimental Staphylococcus aureus endocarditis in rabbits. Journal of Antimicrobial Chemotherapy, 1993, 32, 453-458. | 3.0 | 7 |
| 89 | Treatment of Infection and Colonization Caused by Methicillin-Resistant Staphylococcus aureus. Infection Control and Hospital Epidemiology, 1991, 12, 29-35. | 1.8 | 33 |
| 90 | Endogenous or Exogenous Origin of Platelet-Activating Factor in Cerebrospinal Fluid of Children with Bacterial Meningitis-Reply. Journal of Infectious Diseases, 1991, 163, 1166-1166. | 4.0 | 0 |

| # | Article | IF | Citations |
| --- | --- | --- | --- |
| 91 | Endocarditis Due to Methicillin-Resistant Staphylococcus aureus in Rabbits: Expression of Resistance to Â-Lactam Antibiotics in Vivo and in Vitro. Journal of Infectious Diseases, 1984, 149, 894-903. | 4.0 | 55 |
| 92 | Community-Onset Oxacillin-Resistant Staphylococcus aureus Infection. , 0, , 85-93. | | 0 |